Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy

Shakti D. Shukla; Steven L. Taylor; Peter G. Gibson; Daniel Barker; John W. Upham; Ian A. Yang; Paul N. Reynolds; Sandra Hodge; Alan L. James; Geraint B. Rogers; Jodie L. Simpson

doi:10.1136/thoraxjnl-2020-216331

Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy

Shakti D. Shukla
, Steven L. Taylor
, Peter G. Gibson
, Daniel Barker
, John W. Upham
, Ian A. Yang
, Paul N. Reynolds
, Sandra Hodge
, Alan L. James
, Geraint B. Rogers
, Jodie L. Simpson

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.

Original language	English
Pages (from-to)	733-736
Number of pages	4
Journal	Thorax
Volume	76
Issue number	7
Early online date	7 Jan 2021
DOIs	https://doi.org/10.1136/thoraxjnl-2020-216331
Publication status	Published - 1 Jul 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

asthma
asthma pharmacology
cytokine biology
respiratory infection

Access to Document

10.1136/thoraxjnl-2020-216331Licence: In Copyright

Cite this

@article{ca7634c4690840ada72f9664fd4a1d50,

title = "Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy",

abstract = "Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy. ",

keywords = "asthma, asthma pharmacology, cytokine biology, respiratory infection",

author = "Shukla, \{Shakti D.\} and Taylor, \{Steven L.\} and Gibson, \{Peter G.\} and Daniel Barker and Upham, \{John W.\} and Yang, \{Ian A.\} and Reynolds, \{Paul N.\} and Sandra Hodge and James, \{Alan L.\} and Rogers, \{Geraint B.\} and Simpson, \{Jodie L.\}",

year = "2021",

month = jul,

day = "1",

doi = "10.1136/thoraxjnl-2020-216331",

language = "English",

volume = "76",

pages = "733--736",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "7",

}

TY - JOUR

T1 - Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma

T2 - An AMAZES substudy

AU - Shukla, Shakti D.

AU - Taylor, Steven L.

AU - Gibson, Peter G.

AU - Barker, Daniel

AU - Upham, John W.

AU - Yang, Ian A.

AU - Reynolds, Paul N.

AU - Hodge, Sandra

AU - James, Alan L.

AU - Rogers, Geraint B.

AU - Simpson, Jodie L.

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.

AB - Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.

KW - asthma

KW - asthma pharmacology

KW - cytokine biology

KW - respiratory infection

UR - https://www.scopus.com/pages/publications/85099104624

UR - http://purl.org/au-research/grants/NHMRC/569246

U2 - 10.1136/thoraxjnl-2020-216331

DO - 10.1136/thoraxjnl-2020-216331

M3 - Article

AN - SCOPUS:85099104624

SN - 0040-6376

VL - 76

SP - 733

EP - 736

JO - Thorax

JF - Thorax

IS - 7

ER -

Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this